reta phase 2 was -24.2% at 48 weeks and people quote it like it is a maintenance number
reta phase 2 was -24.2% at 48 weeks and people quote it like it is a maintenance number. That is the headline. The document, the batch and the service are below so you can argue with the method rather than with me.
To save the first four comments: 24.2% and 48 weeks.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Corrections welcome, especially the pedantic ones. Pedantry is how this board earns its reputation.
best — the order this archive was captured in
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Removed the escalation schedule. There is no published protocol for members to follow and inventing one here is exactly what this board does not do.
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.
That is body weight change, not fat mass. The trials report the first and people quote it as the second.
Are you tracking heart rate at all?
Where the evidence actually stands, since every thread here assumes a different answer.
Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.
Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.
the TRIUMPH programme is still running, so anything definitive is premature
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.